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Low-density lipoprotein (LDL) is an important risk factor for coronary artery disease, but itsnstitute
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in 30 coronary arteries excised from 15 subjects who underwent autopsy was performed
using near-infrared ﬂuorescent angioscopy system and using indocyanine green dye as a
biomarker of LDL. The percentage incidence of LDL in 28 normal segments, 24 white pla-
ques (early stage of plaque growth), and 21 yellow plaques (mature stage of plaque) classiﬁed
by conventional angioscopy, was 14.2, 79.1 (p <0.01 vs normal segments and p <0.05 vs
yellow plaques), and 28.5, respectively. Coronary near-infrared ﬂuorescent angioscopy
showed similar results in 7 patients in vivo. Our results suggested that LDL begins to deposit
in the human coronary arterial wall in the early stage of atherosclerosis, increasingly deposits
with plaque growth and decreases in the mature stage; and therefore, molecular therapy
targeting LDL should be started before plaque maturation.  2016 The Authors. Published
by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/). (Am J Cardiol 2016;117:781e786)We have imaged native low-density lipoprotein (LDL)1e7
in excised human coronary plaques using color ﬂuorescent
angioscopy and nile blue dye as a biomarker of LDL,8,9 but
because the dye is lipotrophic, intravascular administration in
patients is not recommended. Our search for a biomarker of
LDL that would be clinically applicable revealed indocyanine
green dye (ICG)10e12 elicits near-infrared ﬂuorescence
(NIRF) characteristic of human LDL only. Therefore, in the
present study, molecular imaging of native LDL in human
coronary plaques by an NIRF angioscopy (NIRFA) sys-
tem13,14 was performed using ICG as a biomarker of LDL
ex vivo and in vivo.Methods
The NIRFA system used in the present study is consisted
of a ﬂuorescence excitation unit, angioscope, ﬂuorescence
emission unit, and camera. The angioscope (modiﬁed Vec-
Mover; Clinical Supply Co, Gifu, Japan) consisted of a 2.5Fr
ﬁberscope containing 6,000 quartz ﬁbers for image guidance
and 300 quartz ﬁbers for light guidance. The ﬁberscope is
incorporated in a 5Fr guiding balloon catheter and is steerable
along a 0.014-inch guidewire, which enables observation of a
coronary segment up to 7 cm in length after a single salineof Japanese Foundation for Cardiovascular Research,
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For NIRFA, the light guide of the angioscope is con-
nected to a ﬂuorescent exciter (developed in collaboration
with Olympus). The light generated by mercuryexenon
(HgeXe) lamp was irradiated through a bandpass ﬁlter
(BPF) of 690 20 nm onto the coronary luminal surface and
the evoked NIRF was received by a chilled charge-coupled
device camera (C5985; Hamamatsu Photonics, Hamamatsu,
Japan) through a dichroic membrane which cuts out light
waves <780 nm, and a band absorption ﬁlter (BAF) of
780 nm, which allows light waves >780 and <880 nm to
pass through. This pair of BPF and BAF was used because
we found by NIRF microscopy (NIRFM) that ICG elicits an
NIRF of human LDL only and not that of other major sub-
stances comprising atherosclerotic plaques.15e18
The obtained images were ampliﬁed by changing the
sensitivity (stepwise from 0 to 10 when NIRF was weak) of
the intensiﬁed charge-coupled device camera controller
(C3510, Hamamatsu Photonics) and displayed on a video
monitor while being recorded on a digital vesatile disc
recorder. The NIRF intensity was arbitrarily deﬁned as
strong, moderate, weak, and absent when the sensitivity
required for imaging was within 5, over 5 and within 7, over
7 and within 9, and over 9, respectively.
The ex vivo study was carried out with the approval of the
ethical committees of the Japan Foundation for Cardiovascular
Research, Tsukuba Memorial Hospital, Funabashi Futawa
Hospital, and Toho University Medical Center and after
obtainingwritten informed consent from the families concerned.
Thirty coronary arteries (15 left anterior descending
arteries, 5 left circumﬂex arteries, and 10 right coronary
arteries) were excised from 15 autopsied cases (62.5 3 years
of age, 4 women, 11 men; cause of death: acute myocardialccess article
4.0/).
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Figure 1. Conventional angioscopic, NIRFA, and immunohistochemical images of a coronary artery from a 65-year-oldmanwith an oldmyocardial infarctionwho died
of pneumonia. Proximal (A) to middle segments (B, C) of the left anterior descending coronary artery were observed by advancing the angioscope distally. (A to C)
Conventional angioscopic images.Arrows indicate the portions observed byNIRFA and immunohistochemical staining; (A-1 toC-1)NIRFA images before ICG and no
NIRF; (A-2 toC-2)NIRFA images after ICG.NIRFwasobserved in yellowplaques (B-2,C-2); (A-3 toC-3) immunohistochemical stainingof the transected surface of the
corresponding portions LDL stained in the yellow plaques (arrows in B-3, C-3). LAD¼ left anterior descending artery; I¼ intima; M ¼ media. Bars ¼ 100 mm.
Figure 2. Percentage incidence of LDL visualized by NIRFA and immu-
nohistochemical staining and its relation to plaque morphology. Incidence
(%) of LDL in white plaque by NIRFA was signiﬁcantly higher than that of
normal segments and yellow plaques, whereas that by immunohistochem-
ical staining in white plaque was signiﬁcantly higher than in normal seg-
ments and showed a tendency to be higher than in yellow plaques.
n ¼ number of preparations examined. *p <0.05 and **p <0.01.
782 The American Journal of Cardiology (www.ajconline.org)infarction [3], diabetic nephropathy [3], cerebral infarction or
bleeding [4], pancreatic carcinoma [2], hepatocellular carci-
noma [1], gastric carcinoma [1], and pneumonia [1]).
A Y connector was introduced into the proximal portion of
each coronary artery for perfusionwith saline solution at a rate
of 20ml/min and then the angioscope was introduced through
the connector into the artery for observation. Initially, con-
ventional angioscopy (details were described elsewhere13)
was carried out to detect plaques. As a result, 45 plaques (24
white plaques and 21 yellow plaques) and 28 normal seg-
mentswere conﬁrmed.Details of angioscopic classiﬁcation of
coronary plaques were described elsewhere.19
After conventional angioscopy, the NIRFA systemwas set
up; a BPF of 690 20 nm and BAF of 780 nm were selected
and a control image was obtained under saline perfusion.
After ceasing the perfusion, 1 ml of 0.1% ICG solution was
injected into the perfusion circuit and 5 minutes later the
perfusion of saline solution was restarted and the target
portion was observed again. Quantitative measurement is
difﬁcult with NIRFA because the target becomes a “ﬁsh eye”
image through the lens attached to the angioscope’s tip.13
Figure 3. Localization of LDL conﬁrmed by immunohistochemical staining.
Relation between localization of LDL (depth from luminal surface) visu-
alized by immunohistochemical staining and NIRFA. LDL stained by
immunohistochemistry and localized within 700 mm in depth of the luminal
surface was imaged by NIRFA in most preparations but one beyond this
depth.
Figure 4. Comparison of NIRFM and immunohistochemical staining for localization of LDL and its relation to the presence or absence of macrophages. Three
adjacent transected sections of a yellow plaque (arrow in A) were used: one for staining with ICG (B), one for immunohistochemical staining of LDL (B-1), and
the other for immunohistochemical staining of M1-macrophages (B-2). Localization of diffusely deposited LDL visualized by NIRFM matched almost
completely with immunohistochemical staining (arrows in B, B-1) but macrophages were not observed there (B-2). LDL showing dotted deposition pattern was
observed in superﬁcial layer of intima (arrowhead in B, B-1), where macrophages were observed (arrowhead in B-2). I ¼ intima and M ¼ media. Bars ¼
100 mm.
Figure 5. Comparison of NIRFM and immunohistochemical staining for
detecting LDL. Localization of LDL visualized by NIRFM using ICG as a
biomarker of LDL and that stained by immunohistochemistry in adjacent
transected surface of coronary plaques coincided in most preparations. n ¼
number of preparations examined. **p <0.01; ***p<0.001.
Coronary Artery Disease/Imaging of LDL in Human Coronary Plaques 783The plaques and normal segments that were observed by
conventional angioscopy and NIRFA were isolated by
transecting the proximal and distal ends along the shorter
axes. Next, the isolated plaques and normal segments were
transected at the center into 2 parts 1 to 2 mm in width. One
part was stored at 20BC for immunohistochemical stain-
ing of LDL. The other part was mounted on a deck glass in
such a way that the transected surface faced the glass for
NIRFM scanning, and 0.1 ml of 106 M ICG solution was
dripped onto the specimen so that it diffused to the trans-
ected surface and stained LDL.
The frozen excised vesselswere cut into 2 sections of 20mm
in thickness on a cryostat (Tissue Tec 3D; Sakura Finetek
Japan, Tokyo). Next, the section adjacent to the part used for
NIRFM was ﬁxed with 4% paraformaldehyde solution and
LDL was stained immunohistochemically with anti-LDL
antibody (anti-LDL antibody ab157795, chicken polyclonal
to LDL, which reacts with human LDL; Abcam Ltd, Tokyo,Japan). Similarly, M1-macrophages in a remaining section
was stained using an anti-CD68 antibody (mouse monoclonal
antibody NCL-CD68-KP1, react with human CD68, Vision
Biosystems Novocastra, New Castle, United Kingdom).20 By
this staining technique, LDL and M1-macrophages were
stained brown. The obtained images were compared with the
corresponding NIRFA and NIRFM images.
After obtaining written informed consent for NIRFA, 7
patients (aged 60.3  2. 4 years; 1 woman, 6 men; 4 patients
with stable angina pectoris and 3 patients with old
myocardial infarction) underwent routine coronary angiog-
raphy, then, conventional angioscopy followed by NIRFA
of the left anterior and/or right coronary artery. Conven-
tional angioscopic and NIRFA systems as described earlier
were used for imaging. After conventional angioscopy, the
light and image guide were connected to ﬂuorescence
excitation and emission units, respectively, without chang-
ing the location of the angioscope tip, and NIRFA was
Figure 6. LDL imaged by NIRFA in a 60-year-old man with stable angina. (A) Coronary angiography (CAG) of right coronary artery; (B) conventional
angioscopic (a-1 to d-1) and NIRFA images (a-2 to d-2) corresponding to a to d in panel A. A yellow plaque (a-1) and a white plaque (c-1) exhibit NIRF. Arrows
indicate the same portions observed by conventional angioscopy and NIRFA.
Figure 7. Relation between percentage incidence of LDL imaged by NIRFA
and plaque morphology in patients. The incidence of LDL in white plaques
was signiﬁcantly higher than that of normal segments and showed a ten-
dency to be higher than that of yellow plaques. n ¼ number of normal
segments or plaques examined. *p <0.05.
784 The American Journal of Cardiology (www.ajconline.org)performed before and after selective intracoronary admin-
istration of 1 ml of 0.1% ICG solution. Details of NIRFA
procedure were described elsewhere.14
The data obtained were tested by chi-square formulae
and were compared among different deposition sites, pat-
terns, and plaque morphology. A value of p <0.05 was
considered to be statistically signiﬁcant.
Results
Figure 1 shows representative NIRFA images of LDL
evoked by ICG and the relation to conventional angioscopic
images and LDL stained by immunohistochemical staining
in the corresponding plaques or normal segments. The
presence or absence of LDL differed from plaque to plaque
and between normal segments.
The percentage incidence of LDL in white plaques (early
stage of plaque growth) was signiﬁcantly higher than that of
yellow plaques (matured stage of plaque) or normal seg-
ments classiﬁed by conventional angioscopy (Figure 2). The
percentage incidence of immunohistochemically stained
LDL in the transected surface of white plaques was also
higher than that in normal segments and showed a tendency
to be higher than that in yellow plaques. Although statisti-
cally not signiﬁcant, the percentage incidence of LDLvisualized by NIRFA was lower than that with immuno-
histochemical staining (Figure 2). The sensitivity and
speciﬁcity of NIRFA for imaging LDL were 87.8% and
100%, respectively.
Compared with immunohistochemical staining, NIRFA
could visualize LDL located within a depth of 700 mm from
Coronary Artery Disease/Imaging of LDL in Human Coronary Plaques 785the luminal surface in most preparations but rarely that
located beyond this depth (Figure 3). As shown in Figures 4
and 5, the localization of LDL in the transected surface of
plaques visualized by NIRFM using ICG coincided with
that on immunohistochemical staining in most preparations.
The sensitivity and speciﬁcity of NIRFM for imaging LDL
were 87.8% and 96.7%, respectively. LDL deposited
diffusely in the intima, where M1-macrophages were not
observed. In a few preparations, LDL showing dotty pattern
was observed in the superﬁcial layer of the intima where
macrophages were observed (arrowheads in Figure 4).
Figure 6 shows images from a patient who underwent
coronary NIRFA. The presence or absence of NIRF of LDL
was not related to plaque color.
The percentage incidence of LDL in white plaques was
signiﬁcantly larger than that of normal segments and
showed a tendency to be larger than that of yellow plaques
(Figure 7). No obvious complications were noted during or
after NIRFA.
Discussion
In the present study, ICG, a low molecular weight dye,
evoked NIRF in the presence of LDL. Although limited to
within 700 mm of the plaque surface, we were able to
visualize native LDL in a given human coronary plaque,
enabling analysis of the relation of LDL content to plaque
morphology.
Vinegoni et al21 observed by NIRFM with a light
wavelength different to that used in the present study that
ICG stained human lipid , loaded macrophages in vitro, and
ICG colocalized with macrophages and lipids in the excised
human carotid atheroma but did not examine which sub-
stance in the macrophages exhibited the NIRF. In the pre-
sent study, LDL showed diffuse deposition pattern and
macrophages did not coexist with LDL in most preparations,
suggesting that the LDL was not conveyed to intima by
macrophages.
When observed with NIRFA or the immunohistochem-
ical staining in the present study, LDL was deposited in
white plaques more frequently than in normal segments or
yellow plaques. This ﬁnding indicates that LDL begins to
deposit in the early stage of atherosclerosis, increasingly
deposits with plaque growth and decreases with plaque
maturation. It is conceivable that LDL is catabolized or
changed by oxidation into oxLDL in mature stage.2
Therefore, we consider that molecular therapy targeting
native LDL within coronary arterial wall should be started
before plaque maturation.
Although imaging is limited to LDL deposited within
700 mm, the present NIRFA system is worth application to
patients because the serious events such as plaque rupture
and erosion which lead to acute coronary syndrome occur
within this depth.
This NIRFA system may contribute to a more objective
understanding of the roles of native LDL in the initiation,
progression, and destabilization of atherosclerotic plaques,
not only in coronary arteries but also in other vessels, and to
evaluation of the effects on LDL within plaques of con-
ventional lipid-lowering and future molecular targeting
therapies.Our study has limitations. Quantitative assessment of
volume and density of LDL in the vascular wall is difﬁcult
for the present NIRFA system because of the following
reasons: (1) the target (LDL) is imaged through a lens
attached on the angioscope tip and therefore the obtained
image is a “ﬁsh eye” image; (2) the LDL deposits are usu-
ally 3-dimensionally distributed and therefore the distance-
related reduction in ﬂuorescence intensity occurs.
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